Inicio・Lista de Acciones・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Cerrado

2.31 -3.35

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

2.27

Máximo

2.35

Métricas clave
By Trading Economics
Ingresos	143M 17M
Empleados	7
EBITDA	-11M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+261.7% upside

Dividendos
By Acuity
Próximas Ganancias	4 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-40M 131M
Apertura anterior	5.66
Cierre anterior	2.31

Minerva Neurosciences Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

17 oct 2026, 23:51 UTC

RBA Kent Speech on October 18 to Address Interest Rates Amid Global Economic Uncertainty and Inflation Concerns.

17 oct 2026, 23:41 UTC

China's Loan Prime Rate Expected to Remain Steady at 3.5% Amid Economic Uncertainties and Weak Credit Growth

17 oct 2026, 23:41 UTC

China's Loan Prime Rate expected to remain stable at 3% amid economic uncertainties and global inflation concerns, with market focus on potential impacts from geopolitical tensions.

17 oct 2026, 23:31 UTC

China's House Price Index YoY release on October 19, 2026, expected to show continued pressure amid economic challenges and rising mortgage rates.

17 oct 2026, 23:11 UTC

Ethereum is trading lower amid broader market pressures from a selloff in technology stocks and rising fears of increased interest rates following inflation data.

17 oct 2026, 23:01 UTC

US Building Permits Forecasted at 1.4 Million Amid Mixed Housing Market Sentiment and High Mortgage Rates

17 oct 2026, 23:01 UTC

Cautious Market Awaits U.S. Housing Starts Data Amid Economic Uncertainties on October 20, 2026

17 oct 2026, 23:01 UTC

U.S. Building Permits Report Set for Release Amid Cautious Market Sentiment and Rising Mortgage Rates

17 oct 2026, 23:01 UTC

U.S. Housing Starts Data Release on October 20 Expected to Show Cautious Forecast of 1.3 Million Amid Rising Mortgage Rates and Economic Uncertainty

17 oct 2026, 22:51 UTC

Brazil's Central Bank to Provide Key Interest Rate Insights on October 19 Amid Global Economic Caution.

17 oct 2026, 22:51 UTC

Japan's Core Inflation Rate Expected to Rise to 2.1% Amid Positive Market Sentiment and BOJ Governor Ueda's Remarks on Monetary Policy Adjustments

17 oct 2026, 22:51 UTC

Japan's Inflation Rate Release on October 22 Expected Amidst Market Optimism and Geopolitical Concerns.

17 oct 2026, 22:41 UTC

Canada's Inflation Rate YoY for September 2026 set to release on October 19, with market focus on persistent high prices and potential impacts on monetary policy.

17 oct 2026, 22:41 UTC

Canada's Core Inflation Rate Release on October 19, 2026, Sparks Cautious Optimism Amid Mixed Economic Sentiment and Rising Interest Rate Concerns.

17 oct 2026, 22:41 UTC

Canada's Inflation Rate Set to Rise 0.2% in September Amidst Market Volatility and Global Price Pressures

17 oct 2026, 22:41 UTC

Mortgage rates hit three-year high at 7.4%, raising concerns over housing affordability and buyer hesitance ahead of upcoming MBA report.

17 oct 2026, 22:31 UTC

Japan's Upcoming Exports YoY Data Release on October 20, 2026, Sparks Cautious Optimism Amid Recovery in Asian Markets and Technology Sector.

17 oct 2026, 22:31 UTC

UK Consumer Confidence Set to Improve Slightly in October Amid Mixed Economic Signals and Inflation Concerns

17 oct 2026, 22:31 UTC

Japan's trade balance forecasted to show a -250 billion yen deficit amid rising import costs and currency weakness, as markets cautiously rebound ahead of October 20 report.

17 oct 2026, 22:11 UTC

Turkey's TCMB Expected to Maintain Interest Rate at 37% Amid Inflation and Geopolitical Tensions on October 22, 2026.

17 oct 2026, 22:01 UTC

News

Ethereum is trading lower, continuing a downward trend amid broader market weakness in technology stocks and concerns over AI financing issues.

17 oct 2026, 22:01 UTC

Correlated Moves

Cardano is trading lower, continuing its downward trend alongside Ethereum, amid broader market weakness and concerns over AI financing issues.

17 oct 2026, 22:01 UTC

News

Ethereum is trading lower, continuing a downward trend amid broader market weakness in technology stocks due to concerns over AI financing issues.

17 oct 2026, 22:01 UTC

Correlated Moves

XRP is declining, continuing a downward trend since Friday, amid broader cryptocurrency market losses linked to concerns over AI financing and inflation data.

17 oct 2026, 22:01 UTC

Correlated Moves

Avalanche is declining amid broader market weakness, influenced by concerns over AI financing issues, while Ethereum also trades lower.

17 oct 2026, 21:21 UTC

Optimism Grows Ahead of Australia's S&P Global Manufacturing PMI Flash Release Amid Strong Market Performance and Positive Economic Sentiment

17 oct 2026, 21:21 UTC

Australia's S&P Global Services PMI Flash on October 22 expected to reflect positive business activity amid rising stock market optimism and supportive global economic sentiment.

17 oct 2026, 21:11 UTC

Spanish Consumer Confidence Index Set for Release on October 19, Amidst Mixed Economic Signals and Rising Inflation Concerns.

17 oct 2026, 21:11 UTC

CBI Business Optimism Index for Q4 2026 Set to Reflect Increased UK Manufacturing Sentiment Amid Positive Industrial Trends and Investor Confidence.

17 oct 2026, 21:11 UTC

UK CBI Industrial Trends Orders Forecast at -20 for October 2026, Indicating Gradual Recovery Amid Improved Investor Sentiment.

Comparación entre iguales

Cambio de precio

Minerva Neurosciences Inc previsión

Precio Objetivo

By TipRanks

261.7% repunte

Estimación a 12 Meses

Media 8.5 USD 261.7%

Máximo 10 USD

Mínimo 7 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Minerva Neurosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Minerva Neurosciences Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.